2.1
Dupilumab (Dupixent, Sanofi Genzyme) is indicated for the 'treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy'.
2 Information about dupilumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics.
Price
2.3
The cost of dupilumab is £1,264.89 per pack of 2×2‑ml syringes of 150 mg/1 ml solution (excluding VAT; BNF online accessed March 2018).
2.4
The company has a commercial arrangement. This makes dupilumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.